SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Pfenex Inc. to Ligand Pharmaceuticals Incorporated

New York, New York--(Newsfile Corp. - August 11, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Pfenex Inc. ("Pfenex" or the "Company") (NYSE: PFNX) stock prior to August 10, 2020.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Pfenex to Ligand Pharmaceuticals Incorporated ("Ligand") (NASDAQ: LGND). Under the terms of the merger, Ligand will acquire all outstanding shares of Pfenex for $12.00 per share in cash. To learn more about the action and your rights, go to:

https://www.zlk.com/mna2/pfenex-inc-information-request-form

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

The Pfenex merger investigation concerns whether the Board of Pfenex has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.

Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/61484